Literature DB >> 31430265

Test-Negative Designs: Differences and Commonalities with Other Case-Control Studies with "Other Patient" Controls.

Jan P Vandenbroucke1,2,3, Neil Pearce4.   

Abstract

Test-negative studies recruit cases who attend a healthcare facility and test positive for a particular disease; controls are patients undergoing the same tests for the same reasons at the same healthcare facility and who test negative. The design is often used for vaccine efficacy studies, but not exclusively, and has been posited as a separate type of study design, different from case-control studies because the controls are not sampled from a wider source population. However, the design is a special case of a broader class of case-control designs that identify cases and sample "other patient" controls from the same healthcare facilities. Therefore, we consider that new insights into the test-negative design can be obtained by viewing them as case-control studies with "other patient" controls; in this context, we explore differences and commonalities, to better define the advantages and disadvantages of the test-negative design in various circumstances. The design has the advantage of similar participation rates, information quality and completeness, referral/catchment areas, initial presentation, diagnostic suspicion tendencies, and preferences by doctors. Under certain assumptions, valid population odds ratios can be estimated with the test-negative design, just as with case-control studies with "other patient" controls. Interestingly, directed acyclic graphs (DAGs) are not completely helpful in explaining why the design works. The use of test-negative designs may not completely resolve all potential biases, but they are a valid study design option, and will in some circumstances lead to less bias, as well as often the most practical one.

Entities:  

Mesh:

Year:  2019        PMID: 31430265     DOI: 10.1097/EDE.0000000000001088

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  22 in total

1.  Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine.

Authors:  Tal Patalon; Sivan Gazit; Virginia E Pitzer; Ottavia Prunas; Joshua L Warren; Daniel M Weinberger
Journal:  JAMA Intern Med       Date:  2022-02-01       Impact factor: 44.409

2.  Existing Data Sources in Clinical Epidemiology: The Danish COVID-19 Cohort.

Authors:  Anton Pottegård; Kasper Bruun Kristensen; Mette Reilev; Lars Christian Lund; Martin Thomsen Ernst; Jesper Hallas; Reimar Wernich Thomsen; Christian Fynbo Christiansen; Henrik Toft Sørensen; Nanna Borup Johansen; Henrik Støvring; Steffen Christensen; Marianne Kragh Thomsen; Anders Husby; Marianne Voldstedlund; Jesper Kjær; Nikolai C Brun
Journal:  Clin Epidemiol       Date:  2020-08-12       Impact factor: 4.790

3.  Incorporating Real-time Influenza Detection Into the Test-negative Design for Estimating Influenza Vaccine Effectiveness: The Real-time Test-negative Design (rtTND).

Authors:  Leora R Feldstein; Wesley H Self; Jill M Ferdinands; Adrienne G Randolph; Michael Aboodi; Adrienne H Baughman; Samuel M Brown; Matthew C Exline; D Clark Files; Kevin Gibbs; Adit A Ginde; Michelle N Gong; Carlos G Grijalva; Natasha Halasa; Akram Khan; Christopher J Lindsell; Margaret Newhams; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay Steingrub; H Keipp Talbot; M Elizabeth Halloran; Manish Patel
Journal:  Clin Infect Dis       Date:  2021-05-04       Impact factor: 9.079

4.  Influenza Vaccine Effectiveness for Prevention of Severe Influenza-Associated Illness Among Adults in the United States, 2019-2020: A Test-Negative Study.

Authors:  Carlos G Grijalva; Leora R Feldstein; H Keipp Talbot; Michael Aboodi; Adrienne H Baughman; Samuel M Brown; Jonathan D Casey; Heidi L Erickson; Matthew C Exline; D Clark Files; Kevin W Gibbs; Adit A Ginde; Michelle N Gong; Natasha Halasa; Akram Khan; Christopher J Lindsell; Samuel K Nwosu; Ithan D Peltan; Matthew E Prekker; Todd W Rice; Nathan I Shapiro; Jay S Steingrub; William B Stubblefield; Mark W Tenforde; Manish M Patel; Wesley H Self
Journal:  Clin Infect Dis       Date:  2021-10-20       Impact factor: 9.079

5.  Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil.

Authors:  Thiago Cerqueira-Silva; Srinivasa Vittal Katikireddi; Vinicius de Araujo Oliveira; Renzo Flores-Ortiz; Juracy Bertoldo Júnior; Enny S Paixão; Chris Robertson; Gerson O Penna; Guilherme L Werneck; Maurício L Barreto; Neil Pearce; Aziz Sheikh; Manoel Barral-Netto; Viviane S Boaventura
Journal:  Nat Med       Date:  2022-02-09       Impact factor: 87.241

6.  Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.

Authors:  Emma K Accorsi; Amadea Britton; Katherine E Fleming-Dutra; Zachary R Smith; Nong Shang; Gordana Derado; Joseph Miller; Stephanie J Schrag; Jennifer R Verani
Journal:  JAMA       Date:  2022-02-15       Impact factor: 157.335

7.  The pitfalls of inferring virus-virus interactions from co-detection prevalence data: application to influenza and SARS-CoV-2.

Authors:  Matthieu Domenech de Cellès; Elizabeth Goult; Jean-Sebastien Casalegno; Sarah C Kramer
Journal:  Proc Biol Sci       Date:  2022-01-12       Impact factor: 5.349

8.  Occupational differences in COVID-19 incidence, severity, and mortality in the United Kingdom: Available data and framework for analyses.

Authors:  Neil Pearce; Sarah Rhodes; Katie Stocking; Lucy Pembrey; Karin van Veldhoven; Elizabeth B Brickley; Steve Robertson; Donna Davoren; Vahe Nafilyan; Ben Windsor-Shellard; Tony Fletcher; Martie van Tongeren
Journal:  Wellcome Open Res       Date:  2021-05-10

9.  Of novel analytic approaches and impactful findings… and an opportunity to pose more questions.

Authors:  David P Moore; Shabir A Madhi
Journal:  Lancet Reg Health West Pac       Date:  2020-09-10

10.  The effectiveness of the 13-valent pneumococcal conjugate vaccine against hypoxic pneumonia in children in Lao People's Democratic Republic: An observational hospital-based test-negative study.

Authors:  Rupert Weaver; Cattram D Nguyen; Jocelyn Chan; Keoudomphone Vilivong; Jana Y R Lai; Ruth Lim; Catherine Satzke; Malisa Vongsakid; Paul N Newton; Kim Mulholland; Amy Gray; Audrey Dubot-Pérès; David A B Dance; Fiona M Russell
Journal:  Lancet Reg Health West Pac       Date:  2020-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.